Literature DB >> 3401619

Biosynthesis of glycosaminoglycans in the human colonic tumor cell line Caco-2: structural changes occurring with the morphological differentiation of the cells.

P Levy1, A Robert, J Picard.   

Abstract

The human colon cancer cell line Caco-2 cultured in vitro displayed morphological differentiation which was shown to be a growth-related event. We have investigated this phenomenon further in relation to the cell surface glycosaminoglycans produced by growing (5-day, i.e., prior to differentiation) and confluent (9-day, i.e., after morphological and functional differentiation) cultures. Neosynthesized [35S]glycosaminoglycans were purified on DEAE-cellulose; at confluency, they were bound more strongly to the column than the corresponding fractions from the growing cells. Analysis of Kav values of heparan sulfate and chondroitin sulfates from growing and confluent cells indicated an increase in chain length of both glycosaminoglycans in morphologically differentiated cells. Heparan sulfate was the main 35S-labeled glycosaminoglycan of the cell surface of both 5-day and 9-day cultures. Paper chromatography of the unsaturated disaccharides obtained by chondroitinase digestion showed that chondroitin sulfate chains were primarily 6-sulfated in the 2 studied extracts. Heparan sulfate chains were isolated as chondroitinase-resistant material and treated with nitrous acid. Analysis of N- and O-sulfate group-related radioactivity showed an increase in the amount of 35S-label in the form of N-sulfate groups and an increase in the O-35S-sulfation pattern in heparan sulfate from morphologically differentiated cells. Thus, the structural features of both chondroitin sulfates and heparan sulfate were significantly different when the growing cells became morphologically differentiated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401619

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  7 in total

1.  Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies.

Authors:  Christopher P Landowski; Pascale Anderle; Duxin Sun; Wolfgang Sadee; Gordon L Amidon
Journal:  AAPS J       Date:  2004-09-07       Impact factor: 4.009

2.  Changes in glycosaminoglycan sulfation and protein kinase C subcellular distribution during differentiation of the human colon tumor cell line Caco-2.

Authors:  P Levy; G Cherqui; A Robert; D Wicek; J Picard
Journal:  Experientia       Date:  1989-06-15

3.  Glycan:glycan interactions: High affinity biomolecular interactions that can mediate binding of pathogenic bacteria to host cells.

Authors:  Christopher J Day; Elizabeth N Tran; Evgeny A Semchenko; Greg Tram; Lauren E Hartley-Tassell; Preston S K Ng; Rebecca M King; Rachel Ulanovsky; Sarah McAtamney; Michael A Apicella; Joe Tiralongo; Renato Morona; Victoria Korolik; Michael P Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-16       Impact factor: 11.205

4.  The stoichiometry of peptide-heparan sulfate binding as a determinant of uptake efficiency of cell-penetrating peptides.

Authors:  Rike Wallbrecher; Wouter P R Verdurmen; Samuel Schmidt; Petra H Bovee-Geurts; Felix Broecker; Anika Reinhardt; Toin H van Kuppevelt; Peter H Seeberger; Roland Brock
Journal:  Cell Mol Life Sci       Date:  2013-11-24       Impact factor: 9.261

5.  Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes.

Authors:  P Levy; A Munier; S Baron-Delage; Y Di Gioia; C Gespach; J Capeau; G Cherqui
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

6.  Glycosaminoglycans in human retinoblastoma cells: heparan sulfate, a modulator of the pigment epithelium-derived factor-receptor interactions.

Authors:  Elena M Alberdi; John E Weldon; S Patricia Becerra
Journal:  BMC Biochem       Date:  2003-02-19       Impact factor: 4.059

7.  In vitro toxicity and formation of early conjugates in Caco-2 cell line treated with clenbuterol, salbutamol and isoxsuprine.

Authors:  A Stammati; P Badino; I De Angelis; G Re; O Vincentini; C Zanetti; F Zucco; G Brambilla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.